Pyrazinamide
- PDF / 169,196 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 164 Views
1 S
Hepatoxicity: case report In a retrospective single-centre study of 98 patients with multi-drug resistant tuberculosis (MDR-TB), enrolled between April 2014 and December 2016, an adult patient [sex and exact age not stated] was described, who developed hepatotoxicity during treatment with pyrazinamide. The patient, who had MDR-TB, started receiving treatment with pyrazinamide once daily [dose and route not stated]. Additionally, the patient was receiving treatment levofloxacin, kanamycin, cycloserine and ethionamide concomitantly. Subsequently, based on the AST, ALT and bilirubin levels, a diagnosis of hepatotoxicity associated with pyrazinamide was made [duration of treatment to reaction onset not stated] and the treatment with pyrazinamide was discontinued [outcome not stated]. Ghimire S, et al. Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: Retrospective single-centre study. BMJ Open 803502432 Respiratory Research 7: No. 1, 2020. Available from: URL: http://doi.org/10.1136/bmjresp-2020-000606
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
